Arrowhead Pharmaceuticals, Inc. (ARWR) H.C. Wainwright 28th Annual Global Investment Conference September 16, 2026 9:00 AM EDT
Company Participants
Dr. Christopher Anzalone – Chairman, CEO & President
James Hamilton – Chief Medical Officer and Head of R&D
Conference Call Participants
Patrick Trucchio – H.C. Wainwright & Co, LLC, Research Division
Presentation
Patrick Trucchio
H.C. Wainwright & Co, LLC, Research Division
Okay. Perfect. Hello, everyone. Good morning, and welcome back to H.C. Wainwright’s 20th Annual Global Investment Conference. I’m Patrick Trucchio, senior health care analyst at H.C. Wainwright. It’s my pleasure to welcome our next speakers, CEO, Chris Anzalone; and CMO and Head of R&D, James Hamilton at Arrowhead Pharmaceuticals.
Arrowhead is a commercial stage pharmaceutical company developing RNA interference or RNAi therapeutics with broad pipeline across cardiometabolic indications and CNS. Arrowhead REDEMPLO, plozasiran, was approved by the U.S. FDA in 2025 as an adjunct to diet to treat triglycerides in adults with familial chylomicronemia syndrome or FCS. At the end of August, Arrowhead presented the full 12-month results of the pivotal Phase III SHASTA-3 and SHASTA-4 trials in severe hypertriglyceridemia, or sHTG, in a hotline late-breaking science session at the European Society of Cardiology Congress and plan to file a supplemental NDA by year-end in sHTG using a priority review voucher. So it’s a huge year for Arrowhead. Pleasure to have you with us.
Question-and-Answer Session
Patrick Trucchio
H.C. Wainwright & Co, LLC, Research Division
Just first, it’s been a transformational last few months, FCS launch, 2 positive pivotal trials, priority review voucher. For those who are new to the Arrowhead story, can you give us an overview of the RNAi platform, why subcutaneous RNAi to the liver became such a robust franchise?
Dr. Christopher Anzalone
Chairman, CEO & President
Sure. First, thanks very much for having us. It’s a pleasure to be
Read the full article here